Success Metrics

Active Trials
4(67%)

Phase Distribution

Ph phase_4
1
17%
Ph phase_1
1
17%
Ph phase_3
3
50%
Ph phase_2
1
17%

Phase Distribution

1

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
3(50.0%)
Phase 4Post-market surveillance
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

4

trials recruiting

Total Trials

6

all time

Status Distribution
Active(5)
Terminated(1)

Detailed Status

Recruiting4
Not yet recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
4
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 11 (16.7%)
Phase 21 (16.7%)
Phase 33 (50.0%)
Phase 41 (16.7%)

Trials by Status

not_yet_recruiting117%
recruiting467%
withdrawn117%

Recent Activity

4 active trials
Showing 5 of 6
recruitingphase_1

Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis

NCT06668493
recruitingphase_3

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

NCT06545955
recruitingphase_3

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06510374
not_yet_recruitingphase_2

Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial

NCT07332351
recruitingphase_3

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

NCT06929286
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06668493Phase 1

Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis

Recruiting
NCT06545955Phase 3

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Recruiting
NCT06510374Phase 3

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Recruiting
NCT07332351Phase 2

Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial

Not Yet Recruiting
NCT06929286Phase 3

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

Recruiting
NCT06390111Phase 4

A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6